Ricardo Ferreira

Dr. Ricardo Ferreira

Red Glead Discovery AB, Medicon Village Building 403, Scheelevagen 2, 223 63 Lund, Sweden
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2013 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira
Daniel J. V. A. dos SantosDaniel J. V. A. dos Santos
Daniel J. V. A. dos Santos

22 May 2012 in Journal of Chemical Theory and Computation
Verified
Journal Article
Closed access
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira
Daniel J. V. A. dos SantosDaniel J. V. A. dos Santos
Daniel J. V. A. dos Santos

10 June 2015 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira
Daniel J. V. A. dos SantosDaniel J. V. A. dos Santos
Daniel J. V. A. dos Santos
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira
Multidrug-resistance (MDR) phenomena are a worldwide health concern. ATP-binding cassette efflux pumps as P-glycoprotein have been thoroughly studied in a frantic run to develop new efflux modulato...

1 September 2013 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
TMTayyab A. Mansoor
Tayyab A. Mansoor
PBPedro M. Borralho
Pedro M. Borralho
SDSaikat Dewanjee
Saikat Dewanjee
SMSilva Mulhovo
Silva Mulhovo
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira

1 September 2011 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
XLXuan Luo
Xuan Luo
DPDavid Pires
David Pires
JAJosé A. Aínsa
José A. Aínsa
BGBegoña Gracia
Begoña Gracia
SMSilva Mulhovo
Silva Mulhovo
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira

24 July 2020 in Molecules
Verified
Journal Article
Open access
PDF file
BGBruno Gonçalves
Bruno Gonçalves
DCDavid Cardoso
David Cardoso
Ricardo FerreiraRicardo Ferreira
Ricardo Ferreira
Multidrug resistance (MDR) in cancer is one of the main limitations for chemotherapy success. Numerous mechanisms are behind the MDR phenomenon wherein the overexpression of the ATP-binding cassette (ABC) transporter proteins P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and multidrug resistance protein 1 (MRP1) is highlighted as a prime factor. Natural product-derived compounds are being addressed as promising ABC transporter modulators to tackle MDR. Flavonoids and terpenoids have been extensively explored in this field as mono or dual modulators of these efflux pumps. Nitrogen-bearing moieties on these scaffolds were proved to influence the modulation of ABC transporters efflux function. This review highlights the potential of semisynthetic nitrogen-containing flavonoid and terpenoid derivatives as candidates for the design of effective MDR reversers. A brief introduction concerning the major role of efflux pumps in multidrug resistance, the potential of natural product-derived compounds in MDR reversal, namely natural flavonoid and terpenoids, and the effect of the introduction of nitrogen-containing groups are provided. The main modifications that have been performed during last few years to generate flavonoid and terpenoid derivatives, bearing nitrogen moieties, such as aliphatic, aromatic and heterocycle amine, amide, and related functional groups, as well as their P-gp, MRP1 and BCRP inhibitory activities are reviewed and discussed.